Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Recommendation of “Buy” from Analysts

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have been assigned an average recommendation of “Buy” from the fourteen research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $84.9091.

A number of brokerages have issued reports on MIRM. JPMorgan Chase & Co. increased their price target on Mirum Pharmaceuticals from $53.00 to $77.00 and gave the stock an “overweight” rating in a research report on Friday, September 12th. TD Cowen raised Mirum Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, September 25th. Wall Street Zen upgraded Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, September 26th. Evercore ISI lifted their price target on shares of Mirum Pharmaceuticals from $77.00 to $89.00 and gave the company an “outperform” rating in a research note on Friday, August 8th. Finally, Morgan Stanley boosted their price target on shares of Mirum Pharmaceuticals from $75.00 to $81.00 and gave the stock an “overweight” rating in a report on Thursday, October 16th.

Mirum Pharmaceuticals Stock Down 0.1%

MIRM opened at $73.07 on Friday. Mirum Pharmaceuticals has a fifty-two week low of $36.88 and a fifty-two week high of $78.54. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. The company has a fifty day moving average of $71.88 and a two-hundred day moving average of $62.07. The stock has a market capitalization of $3.76 billion, a price-to-earnings ratio of -84.96 and a beta of 0.75.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The business had revenue of $133.01 million for the quarter, compared to analyst estimates of $130.11 million. During the same period in the prior year, the company posted ($0.30) EPS. The company’s revenue for the quarter was up 47.1% on a year-over-year basis. Mirum Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts expect that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 9,578 shares of the business’s stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $76.01, for a total transaction of $728,023.78. Following the completion of the sale, the chief financial officer directly owned 39,945 shares in the company, valued at approximately $3,036,219.45. The trade was a 19.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Laura Brege sold 17,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 11th. The shares were sold at an average price of $74.40, for a total value of $1,264,800.00. Following the completion of the transaction, the director owned 15,703 shares in the company, valued at approximately $1,168,303.20. This trade represents a 51.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 14.36% of the stock is owned by insiders.

Institutional Trading of Mirum Pharmaceuticals

Several large investors have recently made changes to their positions in MIRM. CWM LLC lifted its holdings in Mirum Pharmaceuticals by 259.4% in the 1st quarter. CWM LLC now owns 593 shares of the company’s stock valued at $27,000 after purchasing an additional 428 shares in the last quarter. Victory Capital Management Inc. acquired a new stake in shares of Mirum Pharmaceuticals in the first quarter valued at about $213,000. Allianz Asset Management GmbH raised its position in shares of Mirum Pharmaceuticals by 12.1% in the first quarter. Allianz Asset Management GmbH now owns 6,500 shares of the company’s stock valued at $293,000 after buying an additional 700 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Mirum Pharmaceuticals by 3.8% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,998 shares of the company’s stock worth $495,000 after buying an additional 398 shares in the last quarter. Finally, Federated Hermes Inc. boosted its position in Mirum Pharmaceuticals by 9,440.4% during the first quarter. Federated Hermes Inc. now owns 347,366 shares of the company’s stock worth $15,649,000 after acquiring an additional 343,725 shares during the last quarter.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.